Skip to main content

Table 2 Complications and prognosis of all patients between MSD and AD

From: Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial

VariablesMSD (n = 42)AD (n = 69)χ2P-value
Acute GVHD (n, %)0.4350.509
 Yes15 (35.7)29 (42.0)
 No27 (64.3)40 (58.0)
Grade II-IV aGVHD (n, %)3.7880.052
 Yes2 (4.8)12 (17.4)
 No40 (95.2)57 (82.6)
Chronic GVHD (n, %)0.0460.83
 Yes9 (21.4)16 (23.2)
 No33 (78.6)53 (76.8)
IPFD (n, %)0.2740.601
 Yes12 (28.6)23 (33.3)
 No30 (71.4)46 (66.7)
Hemorrhagic cystitis (n, %)3.6900.055
 Yes8 (19.0)25 (36.2)
 No34 (81.0)44 (63.8)
EBV infection (n, %)17.674< 0.001
 Yes1 (2.4)26 (37.7)
 No41 (97.6)43 (62.3)
CMV infection (n, %)13.100< 0.001
 Yes9 (21.4)39 (56.5)
 No33 (78.6)30 (43.5)
Relapse (n, %)5.0560.025
 Yes19 (45.2)17 (24.6)
 No23 (54.8)52 (75.4)
Death (n, %)4.1970.041
 Yes16 (38.1)14 (20.3)
 No26 (61.9)55 (79.7)
Non-relapse mortality (n, %)4.0510.044
 Yes1 (6.3)*5 (35.7)*
 No15 (93.4)*9 (64.3)*
  1. GVHD graft-versus-host disease, IPFD Invasive pulmonary fungal disease, EBV Epstein-Barr virus, CMV Cytomegalovirus; *Non-relapse mortality and relapse mortality as a percentage of total deaths